6 research outputs found

    Composition comprisin Creb3L1/CrebA protein or polynucleotide encoding the CrebA/CREB3L1 for the prevention or treatment of neurodegenerative disease

    No full text
    ๋ณธ ๋ฐœ๋ช…์€ CrebA/CREB3L1 ๋‹จ๋ฐฑ์งˆ ๋˜๋Š” ์ด๋ฅผ ์•”ํ˜ธํ™”ํ•˜๋Š” ํด๋ฆฌ๋‰ดํด๋ ˆ์˜คํ‹ฐ๋“œ๋ฅผ ์œ ํšจ์„ฑ๋ถ„์œผ๋กœ ํ•จ์œ ํ•˜๋Š” ํ‡ดํ–‰์„ฑ๋‡Œ์งˆํ™˜์˜ ์˜ˆ๋ฐฉ ๋˜๋Š” ์น˜๋ฃŒ์šฉ ์•ฝํ•™์  ์กฐ์„ฑ๋ฌผ์— ๊ด€ํ•œ ๊ฒƒ์œผ๋กœ, ๊ตฌ์ฒด์ ์œผ๋กœ CrebA/CREB3L1๋‹จ๋ฐฑ์งˆ์€ Machado-Joseph disease์˜ MJDtr-78Q ๋‹จ๋ฐฑ์งˆ ๋…์„ฑ์œผ๋กœ ์œ ๋ฐœ๋œ ์ˆ˜์ƒ๋Œ๊ธฐ์˜ GOP๊ธฐ๋Šฅ์žฅ์•  ๋ฐ ์›ํ˜•์งˆ๋ง‰ ์†Œ์‹ค์„ ํšŒ๋ณต์‹œํ‚ค๊ณ , C4da ์‹ ๊ฒฝ์„ธํฌ ์ˆ˜์ƒ๋Œ๊ธฐ์˜ ์†Œ์‹ค์„ ์–ต์ œํ•˜๋ฉฐ, ์ˆ˜์ƒ๋Œ๊ธฐ ๊ฐ€์ง€์˜ ํ˜•ํƒœ๋ฅผ ํšŒ๋ณต์‹œํ‚ค๊ณ , polyQ ๋…์„ฑ์œผ๋กœ ์ €ํ•ด๋œ ์†Œํฌ๋งค๊ฐœ์ˆ˜์†ก, ๋ง‰๊ตฌ์กฐํ™”, ์ง€์งˆํ•ฉ์„ฑ๊ณผ CrebA์ด ๊ฐ•ํ•˜๊ฒŒ ์—ฐ๊ด€๋˜์–ด ์žˆ๋Š” ๊ฒƒ์„ ํ™•์ธํ•˜์˜€์œผ๋ฉฐ, ์‚ฌ๋žŒ์œ ๋ž˜ HEK293T ์„ธํฌ์ฃผ์—์„œ CREB3L1 ๋ฐ ์„ธํฌ๋ง‰ ์ˆ˜์†ก๊ณผ ๊ด€๋ จ๋œ Sec13 ๋ฐ Sec23A์˜ ๋ฐœํ˜„์ด polyQ๋…์„ฑ์— ์˜ํ•ด ๊ฐ์†Œํ•˜๋Š” ๊ฒƒ์„ ํ™•์ธํ•จ์œผ๋กœ์จ, ๋ณธ ๋ฐœ๋ช…์˜ CrebA/CREB3L1 ๋‹จ๋ฐฑ์งˆ ๋ฐ ์ด๋ฅผ ์•”ํ˜ธํ™”ํ•˜๋Š” ๋‰ดํด๋ ˆ์˜คํ‹ฐ๋“œ๋Š” ํ‡ดํ–‰์„ฑ๋‡Œ์งˆํ™˜์˜ ์˜ˆ๋ฐฉ ๋˜๋Š” ์น˜๋ฃŒ์šฉ ์กฐ์„ฑ๋ฌผ๋กœ์จ ์œ ์šฉํ•˜๊ฒŒ ์‚ฌ์šฉ๋  ์ˆ˜ ์žˆ๋‹ค.CrebA/CREB3L1(cAMP-response element-binding protein/cAMP-response element-binding protein 3 like 1)๋‹จ๋ฐฑ์งˆ ๋˜๋Š” ์ด๋ฅผ ์•”ํ˜ธํ™” ํ•˜๋Š” ํด๋ฆฌ๋‰ดํด๋ ˆ์˜คํ‹ฐ๋“œ๋ฅผ ์œ ํšจ์„ฑ๋ถ„์œผ๋กœ ํ•จ์œ ํ•˜๋Š” ํ‡ดํ–‰์„ฑ๋‡Œ์งˆํ™˜์˜ ์˜ˆ๋ฐฉ ๋˜๋Š” ์น˜๋ฃŒ์šฉ ์•ฝํ•™์  ์กฐ์„ฑ๋ฌผ๋กœ์„œ,์ƒ๊ธฐ ํ‡ดํ–‰์„ฑ๋‡Œ์งˆํ™˜์€ ์ฒ™์ˆ˜์šด๋™์†Œ๋‡Œ์‹ค์ฆ 1, 2, 6, 7 ๋ฐ 17ํ˜•(spinocerebellar ataxias(SCA) types 1, 2, 6, 7 and 17), ๋งˆ์ฐจ๋„-์กฐ์…‰ ์งˆํ™˜(Machado-Joseph disease, MJD/SCA3), ํ—ŒํŒ…ํ„ด๋ณ‘(Huntington's disease), ์น˜์ƒํ•ต์ ํ•ต๋‹ด์ฐฝ๊ตฌ ์‹œ์ƒํ•˜ํ•ต ์œ„์ถ•์ฆ(dentatorubral pallidoluysian atrophy, DRPLA), X-์—ฐ๊ด€ ์ฒ™์ˆ˜์„ฑ ๊ทผ์œก์œ„์ถ•์ฆ 1(spinal and bulbar muscular atrophy, X-linked 1, SMAX1/SBMA), ๋ฐ ๊ทผ์œ„์ถ•์„ฑ์ธก์‚ญ๊ฒฝํ™”์ฆ(amyotrophic lateral sclerosis)์œผ๋กœ ๊ตฌ์„ฑ๋œ ๊ตฐ์œผ๋กœ๋ถ€ํ„ฐ ์„ ํƒ๋œ ๊ฒƒ์ธ ์•ฝํ•™์  ์กฐ์„ฑ๋ฌผ

    Screening platform for assessing cellular and behavioral defects in Drosophila Melanogaster

    No full text
    For screening drugs or molecules that can modify disease pathophysiology of human disease or conduct drug screening, the use of appropriate in vivo model with low expenditure suitable for large-scale screening is essential. Drosophila Melanogaster, whose genome contain orthologs for 75% of human disease-related genes, offers a quantitative screening platform for assessing both cellular and behavioral defects that are thought to be representative of human diseases like Parkinsonโ€™s disease(PD), Huntingtonโ€™s disease(HD) or amyotrophic lateral sclerosis(ALS). Here, we present the low cost screening analysis platform available for measuring cellular and behavioral defects in Drosophila. This platform can be adapted for the use of therapeutic target discovery process as an economic and powerful in vivo screening tool for the researchers
    corecore